Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) nnounced that data from the Phase 2b clinical trial of LX4211 are being presented today ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE